» Articles » PMID: 36928669

The Association Between C-peptide and Atrial Cardiomyopathy in Nondiabetic Adults: Results from NHANES III

Overview
Journal Heart Vessels
Date 2023 Mar 17
PMID 36928669
Authors
Affiliations
Soon will be listed here.
Abstract

Serum C-peptide exhibits various biological activities. The relationship between C-peptide and atrial cardiomyopathy remains unknown. We aimed to investigate the association between C-peptide level and atrial cardiomyopathy in nondiabetic adults. Our study enrolled 4578 participants without diagnosed diabetes from the Third National Health and Nutrition Examination Survey (NHANES III). Atrial cardiomyopathy was defined as a deep terminal negative P wave in V1 below - 100 µV (more negative), according to the electrocardiogram. The participants were categorized into low C-peptide (≤ 1.46 nmol/L) and high C-peptide (> 1.46 nmol/L) groups, according to the receiver operating characteristic analysis. Odds ratio (OR) and 95% confidence interval (CI) for the association between C-peptide level and atrial cardiomyopathy were generated using multivariate logistic regression analysis. The prevalence of atrial cardiomyopathy was higher in the high C-peptide group than in the low C-peptide group (5.62% vs. 2.31%, P < 0.001, respectively). Multivariate logistic regression analysis showed that participants in the high C-peptide group had a 3.60-fold (95% CI 1.81-6.99) higher risk of atrial cardiomyopathy than those in the low C-peptide group. Per standard deviation increase in C-peptide was linked to a 1.20-fold (95% CI 1.00-1.41) higher risk in atrial cardiomyopathy. High C-peptide level might be an independent risk factor for atrial cardiomyopathy in nondiabetic adults.

Citing Articles

Impact of pemafibrate on lipid profile and insulin resistance in hypertriglyceridemic patients with coronary artery disease and metabolic syndrome.

Nakamura A, Kagaya Y, Saito H, Kanazawa M, Sato K, Miura M Heart Vessels. 2024; 39(6):486-495.

PMID: 38393377 DOI: 10.1007/s00380-024-02363-z.

References
1.
Yosten G, Maric-Bilkan C, Luppi P, Wahren J . Physiological effects and therapeutic potential of proinsulin C-peptide. Am J Physiol Endocrinol Metab. 2014; 307(11):E955-68. PMC: 4254984. DOI: 10.1152/ajpendo.00130.2014. View

2.
Hoekstra J, van Rijn H, Erkelens D, Thijssen J . C-peptide. Diabetes Care. 1982; 5(4):438-46. DOI: 10.2337/diacare.5.4.438. View

3.
Hills C, Brunskill N . Cellular and physiological effects of C-peptide. Clin Sci (Lond). 2009; 116(7):565-74. DOI: 10.1042/CS20080441. View

4.
Rigler R, Pramanik A, Jonasson P, Kratz G, Jansson O, Nygren P . Specific binding of proinsulin C-peptide to human cell membranes. Proc Natl Acad Sci U S A. 1999; 96(23):13318-23. PMC: 23945. DOI: 10.1073/pnas.96.23.13318. View

5.
Li Y, Zhao D, Li Y, Meng L, Enwer G . Serum C-peptide as a key contributor to lipid-related residual cardiovascular risk in the elderly. Arch Gerontol Geriatr. 2017; 73:263-268. DOI: 10.1016/j.archger.2017.05.018. View